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Hepatitis B prevention in Europe: a 
preliminary economic evaluation 
Pierre Van Damme*, Guy Tormans *, Philippe Beutels* and Eddy Van Doorslaer’ 
The World Health Organization (WHO) estimates that about 350 million people in the 
world are carriers of the hepatitis B virus (HBV), 60 million of whom may die from liver 
cancer and about 45 million from cirrhosis. In the WHO European Region, which has a 
total population of 839 million inhabitants, the average number of acute hepatitis B cases 
reported in 1991 was approximately 160 000, giving an incidence of 19 per 100 000 popu- 
lation. This incidence rate varies from 5 per 100 000 in western Europe to 22 per 100 000 
in central Europe and 92 per 100 000 in eastern Europe. Because of under-reporting and 
the fact that two-thirds of infections are asymptomatic, the reported incidence rate consid- 
erably underestimates the true incidence of HBV in Europe. For this reason, we may multi- 
ply the number of reported cases by a factor of 6 (by 2 for under-reporting and by 3 for the 
symptomaticlasymptomatic ratio): an estimated 900 000 to I 000 000 infections of HBV 
occur in Europe each year. Approximately 90 000 chronic infections will develop from these 
new cases. The spread of HBV can be controlled by universal infant or adolescent vaccina- 
tion. A decision-tree-based analytical model was used to assess the clinical and economic 
impact of these two interventions. The model took into account incidence and prevalence 
rates of HBV natural history of infection, compliance and effectiveness of vaccination, and 
direct and indirect costs. Data were obtained from the literature and from a WHO European 
survey. The cost-effectiveness ratio amounts to X6443 and ~C4745 per infection prevented 
for neonatal and adolescent vaccination, respectively. The results from these calculations 
show that neither vaccination of neonates or of adolescents is cost-saving. However, the 
cost-effectiveness - i.e. the cost incurred to prevent an HBV infection is of an acceptable 
magnitude for both strategies. 
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INTRODUCTION 
With more than 350 million carriers estimated world-wide, 
hepatitis B is one of the world’s major health problems’. 
The prevalence of hepatitis B virus (HBV) infection varies 
considerably in different geographic parts of the world. In 
Europe, the annual number of HBV infections is estimated 
to approach 1 million. In an attempt to provide Europe’s 
decision makers with an insight on the economic impact of 
the disease, this paper evaluates the economic conse- 
quences of different vaccination strategies against HBV 
infection in Europe. In order to do so a simulation model 
has been built. A number of the input parameters to the 
model were assessed after consulting several experts from 
the World Health Organization (WHO) and the London 
School of Hygiene and Tropical Medicine. 
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ESTIMATING THE INCIDENCE OF HEPATITIS B 
VIRUS INFECTION 
If we extrapolate recent data from 30 countries of the 
European Region of the WHO to the whole of the region, 
consisting of 50 countries, about 160 500 cases of acute 
hepatitis B are reported each ye&. Since the incidence of 
reported acute cases varies greatly between western, cen- 
tral and eastern Europe (Table I), this figure is a weighted 
average. Analogous to Alter et al3 and West et aL4 in the 
USA, we estimated the total number of infections that 
actually occur by upgrading by a factor of 6: multiplication 
by ,a factor of 2 is a conservative correction for under- 
reporting and multiplication by a factor of 3 corrects for 
the (more frequent) asymptomatic cases. This results in an 
estimated 900 000 to 1 0 000 infections annually, with 
an incidence ranging from 29 per 100 000 population in 
western Europe to 523 per 100 000 in eastern Europe. The 
weighted average incidence for the WHO European region 
is 115.4 per 100 000 inhabitants. 
Epidemiological data from the WHO and from available 
literature on the specific countries were used to establish the 
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Table 1 Extrapolation of figures on the incidence of HBV in 30 European countries to the entire European region of WHO (1988-1991)* 
Area No. of reported 
cases of acute 
hepatitis B (A) 
Incidence of acute 
cases of hepatitis B 
(per 100 000) 
Estimated No. of 
HBV infections 
(A x 6) 
Estimated incidence 
of HBV infection 
(per 100 000) 
Western Europe 18700 5 110000 29 
Central Europe 68 800 22 550 000 136 
Eastern Europe 53 000 92 300 000 523 
Total 160500 19’ 960 000 115s 
Figures are rounded 
Weighted average 
number of individuals at risk in a populations-‘. Figure 1 
illustrates the probability of annual outcomes of HBV infec- 
tion for the WHO European xegionp-‘3. It shows that, of the 
900 000 to 1 000 000 HBV-infected persons, about 90 000 
are expected to become chronic carriers, 24 000 of whom 
are expected to die from the consequences of chronic liver 
disease, i.e. cirrhosis and hepatocellular cancer. 
THE SIMULATION MODEL AND ITS INPUT 
PARAMETERS 
To evaluate the potential of HBV vaccination in Europe, a 
simulation model has been developed based on WHO data. 
Instead of using the large and unwieldy group of all 
European newborns, a hypothetical cohort of 100 000 
newborns was chosen. The model uses data which are 
averaged for the whole region. 
The different vaccination strategies that were compared 
were: (a) doing nothing; (b) vaccinating neonates; (c) vac- 
cinating adolescents (aged 10 years). 
The expected costs (1990 price levels) include direct 
medical costs, consisting primarily of treatment costs for 
disease (physician visits, medication, laboratory tests and 
hospitalization). On the basis of our epidemiological and 
cost data, it can be estimated that the treatment of an aver- 
age HBV-infected person (including those who do not need 
treatment at all) costs approximately f 228. Direct costs also 
include intervention costs, which arise only under the two 
intervention strategies. They are made up of the costs of the 
vaccine dose and the associated administration costs. 
In accordance with many other cost-effectiveness and 
benefit-cost studiesi4, the analysis was also made with 
inclusion of indirect costs (i.e. production losses due to 
morbidity and mortality). 
The effects of the different strategies are expressed in 
the model as the number of cases prevented of: HBV 
infection; chronic active carriers; cirrhosis; or hepatocellu- 
lar carcinoma; or as the number of life years lost or 
gained. For each strategy these five possible effects are 
calculated, after which they can be balanced against the 
expected costs and a comparison can be made between the 
respective cost-effectiveness and benefit-cost ratios. 
The attack rate varies according to age, with a low inci- 
dence in neonates and a higher incidence in adolescents, 
due to the potential for sexual transmission at the later age. 
We assume a prevalence of HBV infection of 0.03% 
among neonates, which represents perinatal infection. 
The cost of the vaccine, which is of great influence in 
the cost-effectiveness analysis, appears to be different for 
each country in Europe. The model uses average costs per 
person of f7.50 for the vaccine and f5 for administration 
and implementation. 
Vaccination compliance was assumed to be as follows: 
90% for the first dose, 80% for the second dose and 70% 
HBV infections per year 
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Figure 1 Annual probability of outcome of HBV infection in the 
European Region of WHO 
for the booster dose. The model assumes a protection rate 
of 40% after the first dose and 60% after the second dose. 
Those who complete the course are assumed to have a 
95% protection against becoming a carrier for a period of 
more than 30 years, which is the time span adopted for this 
study. The same time span was used in a similar study by 
Bloom et al. in the USAIS. 
RESULTS OF THE MODEL 
Number of infections 
By doing nothing, about 650 of the 100 000 newborns 
will become infected during the 30-year period. Most of 
these infections are asymptomatic; some are mild and 
some are severe, only very few are fulminant. By vaccinat- 
ing neonates, about 220 infections will still occur, whereas 
adolescent vaccination will result in about 280 infections 
in the cohort. These infections are caused by non-compli- 
ance and by the less than 100% protection rate for those 
who fully comply with the vaccination schedule. So about 
60 cases that would have been prevented by the vaccina- 
tion of neonates are missed when the intervention takes 
place during adolescence. 
The outcome can be expressed both as the number of 
expected infections over time and, depending on the 
choice of strategy, as the number of chronic outcomes. 
Doing nothing results in 140 carriers out of the 100 000 
newborns. With compliance at less than 100% there will 
still be 46 cases of carriers when infants are immunized. 
Adolescent vaccination results in 96 cases of carriers. 
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Figure 2 Age-specific annual number of infections as predicted by the model. X, Doing nothing; 0, neonatal vaccination; A, adolescent 
vaccination 
The expected age-related numbers of annual infections 
per 100 000 for each of the strategies are summarized in 
Figure 2. The difference between doing nothing and the 
two intervention strategies is more than doubled after the 
age of 14 years, when sexual contact becomes an impor- 
tant transmission route for HBV. 
RESULTS OF THE MODEL 
Cost-effectiveness and benefitxost ratios 
Doing nothing incurs direct medical costs and indirect 
morbidity and mortality costs for 650 cases of hepatitis. 
Immunization of neonates generates costs of intervention 
as well as costs for treatment of non-prevented cases due 
to non-compliance and non-response to vaccine. Similarly, 
with adolescent immunization, costs are incurred for inter- 
vention and for treatment due to infection before vaccina- 
tion, non-compliance and non-response to vaccine. Under 
the two preventive strategies, indirect costs due to remain- 
ing morbidity and mortality should also be evaluated. 
The incremental cost is the difference between the costs 
related to the implementation of vaccination and the costs 
related to infections prevented by vaccination. The 
cost-effectiveness is the ratio of the incremental cost to 
the resulting effects of the vaccination strategy. For 
neonatal vaccination, the direct incremental cost amounts 
to f2.8 million for 434 HBV infections prevented, or a 
cost-effectiveness of f6443 per infection prevented. For 
adolescent vaccination, the incremental cost is El.8 mil- 
lion to prevent 374 HBV infections, or g4745 per infec- 
tion prevented. When the associated indirect costs due to 
morbidity are included, these cost-effectiveness ratios 
decrease to f5914 and f4340 for neonatal and adolescent 
vaccination, respectively. 
The difference in cost when vaccinating at different ages 
is mostly due to the fact that there is a time lag between 
vaccination and health gain. If adolescents are vaccinated, 
the health gain is soon apparent because of the predomi- 
nance of sexual transmission of HBV. If neonates are vac- 
cinated, the health gain becomes apparent only lo-20 
years later. It is important to note that all future costs were 
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discounted at 5% (effects were not discounted at baseline). 
If the indirect costs due to premature mortality are also 
included, the neonatal strategy becomes more cost-effective 
(f2013 per infection prevented) than the adolescent strategy 
(E2940 per infection prevented). This is because non-vacci- 
nation in neonates allows HBV more opportunity to develop 
into a chronic state, with a resulting higher mortality. 
These results are confirmed by the benefit-cost ratios. 
Although they are all ~1, indicating that there will be no 
financial return on investment, there is a higher 
benefit-cost ratio for the neonatal strategy. With inclusion 
of direct costs, indirect costs due to morbidity and indirect 
costs due to mortality, respectively, the benefit-cost ratios 
are 0.05; 0.13 and 0.70 for the neonatal strategy versus 
0.04; 0.11 and 0.40 for the adolescent strategy. 
CONCLUSION 
The results from the simulations show that neither vacci- 
nation of neonates nor vaccination of adolescents is cost- 
saving. However, the cost-effectiveness, i.e. the cost 
which needs to be incurred to prevent an HBV infection, is 
of an acceptable magnitude for both strategies. The health 
gains, i.e. the prevention of more than one-half of the HBV 
infections and of the chronic outcomes, seem to be suffi- 
cient to justify either of both intervention strategies. Since 
the neonatal vaccination strategy prevents more infections 
(acute and chronic), albeit at a later stage in time, and pro- 
duces a comparable cost-effectiveness ratio (or a better 
one when all indirect costs are included) and a better bene- 
fit-cost ratio than the adolescent vaccination strategy, it 
seems that the neonatal strategy should be preferred to the 
adolescent strategy. This is confirmed by a comparable 
country-specific study in the USA15. It is, however, impor- 
tant to bear in mind that the enormous variations in both 
incidence and cost data between the different European 
countries make it very difficult to come to a single 
irrefutable verdict on the cost-effectiveness of HBV vacci- 
nation for all European countries. It is our opinion that it is 
in the interest of each country to reach an individual deci- 
sion in this matter, based on its own data. 
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